Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.
August 03 2015 - 9:00AM
Business Wire
Company enters into a collaboration
agreement with Robert H. Lurie Comprehensive Cancer Center of
Northwestern University and the Northwestern Medicine Developmental
Therapeutics Institute as part of the I-O RPM program
I-O RPM program to focus on patients with
high risk, poor prognostic cancers
Bristol-Myers Squibb Company (NYSE:BMY) today announced the
establishment of the Immuno-Oncology Rare Population Malignancy
(I-O RPM) program in the U.S. The I-O RPM program is a
multi-institutional initiative with academic-based cancer centers
focused on the clinical investigation of Immuno-Oncology
therapeutics as potential treatment options for patients with high
risk, poor prognostic cancers, defined as a rare population
malignancy. A rare population malignancy is a subpopulation within
a higher incident disease population (e.g. BRCA 1 and 2 breast
cancer). These patients have aggressive disease with an increased
potential for early metastasis to multiple sites and/or are
initially refractory or subject to early recurrences with
conventional cancer therapies.
As part of the I-O RPM program, Bristol-Myers Squibb, the Robert
H. Lurie Comprehensive Cancer Center of Northwestern University
(Lurie Cancer Center) and the Northwestern Medicine Developmental
Therapeutics Institute (NMDTI) are pleased to announce that they
have entered into a collaboration agreement. The Lurie Cancer
Center and NMDTI will conduct a range of early phase clinical
studies and Bristol-Myers Squibb will fund positions within the
NMDTI Developmental Therapeutics Fellowship program.
“Complementing our broad research and development programs
through innovative collaborations with partners such as the Lurie
Cancer Center and NMDTI has been a fundamental component to our
commitment to leading advances in Immuno-Oncology,” said Laura
Bessen, M.D., head of U.S. Medical, Bristol-Myers Squibb.
“Cooperation between industry and research partners of this caliber
offers a tremendous opportunity to further strengthen our
scientific and clinical understanding of the role immunotherapies
can play in the treatment of a broad range of cancers.”
“Immunotherapy is rapidly evolving and has an enormous promise
for cancer patients. This collaborative effort with Bristol-Myers
Squibb will further strengthen our efforts to develop innovative
new therapies against a wide variety of malignancies,” said
Leonidas C. Platanias, M.D., Ph.D., director of the Lurie Cancer
Center.
“The Rare Population Malignancy Program is a very timely and
important initiative. The ability to rapidly investigate the
clinical utility of Bristol-Myers Squibb’s Immuno-Oncology agents,
as single agents or in combinations, including with therapies from
other sources, is a powerful accelerant to our programs. The focus
on malignancies that are otherwise relatively under-investigated in
therapeutic terms is particularly important and satisfying for all
involved in this collaboration,” said Francis J. Giles, M.D.,
director of the NMDTI and deputy director of the Lurie Cancer
Center.
Immuno-Oncology is an innovative approach to cancer research and
treatment that is designed to harness the body’s own immune system
to fight cancer. The I-O RPM program will focus on significant
areas of high unmet need marked by poor outcomes among patients
with these cancers. Existing clinical research, including studies
being conducted by the Lurie Cancer Center and NMDTI, provide a
strong rationale for further research into the potential of
immunotherapies for these cancers.
About Bristol Myers Squibb
The I-O RPM builds on Bristol-Myers Squibb’s formation in 2012
of the International Immuno-Oncology Network (II-ON). II-ON is a
global collaboration between Bristol-Myers Squibb and academia
focused on facilitating the translation of scientific research
findings into clinical trials and, eventually, clinical
practice.
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information, please visit www.bms.com or follow us on Twitter at
http://twitter.com/bmsnews.
About the Robert H. Lurie Comprehensive Cancer Center of
Northwestern University
The Robert H. Lurie Comprehensive Cancer Center of Northwestern
University is one of only 45 National Cancer Institute
(NCI)-designated "Comprehensive" cancer centers in the nation. In
addition, the Lurie Cancer Center is a founding member of the
National Comprehensive Cancer Network (NCCN), an alliance of 25 of
the world's leading cancer centers dedicated to improving the
quality and effectiveness of care provided to patients with cancer
and part of the Big Ten Cancer Research Consortium, a network of
academic institutions working together on highly translational
clinical trials using the expertise of Big Ten universities. The
Lurie Cancer Center is affiliated with four leading teaching
hospitals in Chicago — Northwestern Memorial Hospital, Ann &
Robert H. Lurie Children's Hospital of Chicago , the Rehabilitation
Institute of Chicago, and the Jesse Brown Veteran's Affairs Medical
Center, treating more than 10,000 new patients with cancer each
year. The Lurie Cancer Center receives a cancer center support
grant from the NCI of the National Institutes of Health (P30
CA060553).
About the Northwestern Medicine Developmental Therapeutics
Institute
The Northwestern Medicine Developmental Therapeutics Institute
(NMDTI) provides infrastructure and expertise to accelerate the
developmental therapeutics process. With dedicated patient care
facilities, experienced physician-scientists, and specialized
advanced practice providers, pharmacists, and allied staff, NMDTI
brings a large external pipeline of investigational agents to our
patients while accelerating the development of Northwestern
University’s internal pipeline of novel therapies. The NMDTI
Developmental Therapeutics Fellowship, supported by the Woman’s
Board of Northwestern Memorial Hospital, focuses on nurturing
physician scientists whose career is dedicated to the development
of novel approaches to curing cancer.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Among other risks, there can be no guarantee
that the immunotherapies discussed in this release will be
successfully developed or approved. Forward-looking statements in
this press release should be evaluated together with the many
uncertainties that affect Bristol-Myers Squibb's business,
particularly those identified in the cautionary factors discussion
in Bristol-Myers Squibb's Annual Report on Form 10-K for the year
ended December 31, 2014 in our Quarterly Reports on Form 10-Q and
our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150803005659/en/
Bristol-Myers SquibbMedia:Sarah Koenig,
609-252-4145sarah.koenig@bms.comorInvestors:Ranya Dajani,
609-252-5330ranya.dajani@bms.comorNorthwestern UniversityBob
Storer, 847-491-4889storer.rowley@northwestern.edu
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024